cbt102-a
Phenylketonuria
Children's Hospital of Fudan UniversityEarly Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the Phenylketonuria cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sapropterin Dihydrochloride Sohag University | Phase 4 | A |
PHENYLASE BioMarin Pharmaceutical | Phase 4 | A |
Ravpal-Peg BioMarin Pharmaceutical | Phase 2 | BB |
Repinatrabit Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | BB |
ESCHERICHIA COLI STRAIN SYNB1618 Synlogic | Phase 2 | BB |
View all 29 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →